MedTrace Logo

Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine A

NCT01136551 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2010-06-03

No results posted yet for this study

Summary

The purpose of this study is to develop oral controlled release formulation of Huperzine A that will provide optimal pharmacokinetic profile of the drug enhancing safety and compliance, as possible cure to neurodegenerative disorders.

Conditions

  • Healthy
  • Bioavailability

Interventions

DRUG

Huperzine A

Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.

Sponsors & Collaborators

  • Hebrew University of Jerusalem

    collaborator OTHER

  • Hadassah Medical Organization

    lead OTHER

Principal Investigators

  • Michael Friedman, Proffesor · Institute for Drug Research, Hebrew University of Jerusalem, Israel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-01-31
Completion
2011-04-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01136551 on ClinicalTrials.gov